Vascular Impact of Dapagliflozin in CKD Patients (DAPAVASC)

NCT04930549 PHASE2 COMPLETED

This study aims to determine whether dapaglfiflozin 12-week administration is associated with a beneficial impact on the vasculature of patients with chronic kidney disease.

Details

Lead sponsor	University Hospital, Rouen
Phase	PHASE2
Status	COMPLETED
Enrolment	32
Start date	Tue Oct 18 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Sep 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Renal Insufficiency, Chronic

Interventions

• Dapagliflozin 10Mg Tab
• Placebo
• impedance cardiography
• Applanation tonometry
• post-ischemic hyperemia of forearm
• haemodynamics parameters

Countries

France